Cancer Vaccine Coalition

Name

Cancer Vaccine Coalition

Legal name

Cancer Vaccine Coalition

Website

https://cancervaccinecoalition.org

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Cancer Research Non-Profit Advocacy

NAICS

Voluntary Health Organizations (813212), Social Advocacy Organizations (8133)

SIC

Services-Membership Organizations (8600), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

akta.pro secondary industries

Immunization & Vaccine Delivery Programs (BPADAIAB), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)

Keywords

• Cancer vaccine research
• Clinical trial funding
• Breast cancer prevention
• Cancer immunotherapy advocacy
• Nonprofit research coalition

Headquarters

HQ city

Middlebury

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Foundation Grants and Donations: The organization raises funds through grants from family foundations and partnerships with other cancer research non-profits. The $1 million grant from the Brian and Sheila Jellison Family Foundation, administered through the V Foundation for Cancer Research, exemplifies this funding model.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Cancer Vaccine Coalition is a 501C3 non-profit organization that funds and coordinates cancer vaccine research and clinical trials, with a specific focus on cancer interception strategies to prevent cancer recurrence. The organization mobilizes patients, researchers, and donors through advocacy and partnerships, and channels grants (e.g., a $1 million commitment for the INTERCEPT-HER2 Phase II clinical trial at MD Anderson Cancer Center) to advance therapeutic vaccines for HER2+ breast cancer and other high-risk cancers. As of April 2026, CVC has integrated with the Parker Institute for Cancer Immunotherapy (PICI) to accelerate its mission through PICI's coordinated network of leading cancer centers.

Product overview

Cancer Vaccine Coalition (CVC) is a non-profit coalition organization focused on accelerating the development and delivery of cancer vaccines through funding research, building global collaborations, and supporting clinical trials. The organization does not operate a traditional software product or technology platform; instead, it functions as a research accelerator and grant-making entity that partners with leading cancer research institutions to advance cancer interception strategies. CVC's primary activities include funding clinical trials such as the INTERCEPT-HER2 trial at MD Anderson Cancer Center, strategic partnerships with organizations like the Parker Institute for Cancer Immunotherapy and the V Foundation for Cancer Research, and awareness/mobilization efforts led by founder Kristen Dahlgren. As of 2026, CVC has integrated with the Parker Institute for Cancer Immunotherapy, with founder Kristen Dahlgren joining PICI's executive leadership team as Chief External Affairs Officer.

Differentiator

Problem solved

Functional benefit

Products and services

• INTERCEPT-HER2 Phase II Clinical Trial Funding Program A funded clinical trial initiative supporting the Phase II INTERCEPT-HER2 study at MD Anderson Cancer Center, targeting HER2+ breast cancer patients at risk of recurrence. The program combines circulating tumor DNA blood test detection with a therapeutic vaccine designed to intercept cancer before metastatic spread. Intended for breast cancer patients, oncology researchers, and clinical trial sponsors focused on cancer interception.
• Cancer Vaccine Research Coordination and Advocacy A non-profit coalition service that mobilizes patients, researchers, and donors to accelerate cancer vaccine development through global collaboration, advocacy, and public awareness campaigns. Serves cancer patients, survivors, researchers, and donors seeking to advance therapeutic cancer vaccine research and access.

Quantifiable outcome

• Up to 30% of early-stage breast cancer cases recur as metastatic disease

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core.

• Parker Institute for Cancer Immunotherapy (PICI)coreStrategic or Co-development Partner · 14 April 2026Strategic integration where Cancer Vaccine Coalition joins PICI as a catalyst organization. CVC founder Kristen Dahlgren joined PICI as Chief External Affairs Officer. The integration combines research networks and resources to accelerate cancer vaccine development and delivery, particularly for high-risk cancer recurrence patients. PICI was founded in 2016 by tech pioneer Sean Parker.
• V Foundation for Cancer ResearchcoreStrategic or Co-development Partner · 30 March 2026Strategic partnership for administering the $1 million grant toward the INTERCEPT-HER2 Phase II clinical trial at MD Anderson Cancer Center. The V Foundation serves as the administrative partner for this cancer interception research funding.
• The University of Texas MD Anderson Cancer CentercoreStrategic or Co-development PartnerLeading cancer research institution conducting the Phase II INTERCEPT-HER2 clinical trial. The trial uses blood tests to detect circulating tumor DNA in HER2+ breast cancer patients and administers a therapeutic vaccine designed to prevent cancer recurrence before metastasis.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Susan G. Komen: Largest breast cancer-focused non-profit, funding research (including vaccine-adjacent work), patient support, and advocacy. Comparable as a breast cancer-specific funder with research and awareness arms.
• National Breast Cancer Coalition (NBCC): Breast cancer-focused advocacy and research funding coalition that has historically mobilized patients, researchers, and policymakers to accelerate breast cancer research. Directly comparable as a disease-specific coalition organization driving collaboration and funding for breast cancer breakthroughs.
• Cancer Research Institute (CRI): Non-profit specifically dedicated to funding cancer immunotherapy research, including therapeutic cancer vaccines. Directly comparable given shared focus on immune-based cancer treatments and funding of investigator-initiated trials in the vaccine/immunotherapy space.
• V Foundation for Cancer Research: Major cancer research grant-making non-profit and CVC's administrative partner for the Jellison Foundation grant. Directly comparable as a peer non-profit that raises philanthropic capital and channels it into investigator-initiated cancer research and clinical trials.
• Parker Institute for Cancer Immunotherapy (PICI): Now CVC's parent organization. PICI funds and coordinates cancer immunotherapy research across a network of top cancer centers. Most directly comparable as both fund clinical research and share the cancer immunology mission; CVC's mission is now embedded within PICI.

Broad incumbents

• American Cancer Society: Large-scale cancer non-profit funding research, advocacy, and patient support. PICI's new CEO (Karen Knudsen) was formerly ACS CEO. Overlaps with CVC in funding research and public health mobilization around cancer.
• Stand Up To Cancer (SU2C): High-profile cancer research fundraising non-profit that funds multi-institutional "Dream Teams" and clinical trials, including immunotherapy programs. Comparable mission of accelerating translational cancer research via collaborative funding, though broader in scope than CVC's vaccine focus.
• Biden Cancer Initiative / Cancer Moonshot: Federal/public-sector initiative to accelerate cancer research progress, including immunotherapy and prevention. Comparable as a high-visibility mission to compress timelines for cancer breakthroughs, though at vastly larger scale and government-backed.

Emerging players

• Lustgarten Foundation: Dedicated pancreatic cancer research funder with a collaborative, network-based model for advancing immunotherapy and early detection. Comparable as a disease-specific, donor-funded research catalyst organization that partners with academic centers.
• Prevent Cancer Foundation: Non-profit focused specifically on cancer prevention and early detection, funding research and education programs. Comparable via overlapping "interception" mindset - intervening before disease progresses - though with a broader modality portfolio than CVC's vaccine focus.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cancer Vaccine Coalition